Claims

1. An oral pharmaceutical administration form containing ibandronate or a physiologically tolerable salt thereof as active substance, characterized in that the administration form consists of an active substance-containing inner portion enclosed in such fashion by a coat free of active substance that rapid release of the active substance takes place.

2. The administration form according to claim 1, characterized in that at least 30% of the contained dose of active substance, but preferably at least 75% is released within 2 hours, preferably within 1 hour, and particularly preferred within a half hour upon contact with an aqueous medium at a pH of from 1 to 7.4.

3. The administration form according to claim 1 or 2, characterized in that the active substance-containing inner portion consists of a tablet, capsule, granulate, pellet, or powder in admixture with adjuvants or as a pure active substance.

4. The administration form according to claim 3, characterized in that the coat free of active substance is a film containing at least one ingredient from one of the following groups of substances: cellulose, cellulose derivatives, dextrins, starch and starch derivatives, polymers based on other carbohydrates and derivatives thereof, natural gums such as gum arabic, xanthans, alginates; polyacrylic acid, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, polymethacrylates and derivatives thereof (Eudragit®), chitosan

and derivatives thereof, shellac and derivatives thereof, fats and waxes.

5. The administration form according to claim 4, containing at least one of the following cellulose derivatives: methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, sodium carboxymethylcellulose, ethylcellulose.

6. The administration form according to claim 4 or 5, containing methylhydroxypropylcellulose.

7. The administration form according to one of claims 1 - 4, containing at least one polymethacrylate.

8. The administration form according to claim 7, containing at least one of the following polymethacrylates: cationic copolymerizate of dimethylaminoethyl methacrylate with neutral methacrylic esters; copolymerizate of acrylic and methacrylic esters; copolymerizate of ethyl acrylate and methyl methacrylate.

9. The administration form according to one of claims 1 - 8, wherein the coat is a film-forming agent of a type having gastric juice-resistant properties, and the layer thickness is that thin or of such nature as to form pores so that essentially, no gastric juice-resistant properties of such a coat will result.

10. The administration form according to claim 9, characterized in that at least one of the following film-forming agents is employed: anionic copolymerizate of methacrylic acid and methyl methacrylate, cellulose acetate phthalate, cellulose acetate trimellitate and methylhydroxypropylcellulose phthalate, polyvinyl acetate phthalate.

11. The administration form according to one of claims 1 - 10, characterized in that the film contains at least one plasticizer, pore-forming agent, filling agent, coloring agent, pigment, antifoam agent, anti-stick agent.

12. The administration form according to one of claims 1 - 11, which can be obtained by applying the coat free of active substance using press coating, the applied coat containing at least one ingredient according to claims 4 - 11, or at least one ingredient from one of the following groups: carbohydrates, sugar alcohols, inorganic phosphates, sulfates, carbonates.

13. The administration form according to claim 12, containing in its coat at least one binding agent, filling agent, disintegrant, flow agent, release agent, taste improver, pigment, or coloring agent.

14. The administration form according to one of claims 1 - 13, which can be obtained by applying the coat free of active substance by tablet coating, the applied coat containing at least one ingredient according to claims 4 - 11.

15. The administration form according to claim 14, containing at least one of the following ingredients: bentonite, calcium sulfate, fat, colloid silicic acid, magnesium oxide, palatinite, polyethylene glycol, polyethylene glycol fatty acid ester, wax.

17. The administration form according to one of claims 1 - 11, which can be obtained by applying the coat free of active substance by encapsulating, the applied coat containing at least one of the ingredients gelatin, starch or cellulose derivatives.

18. The administration form according to one of claims 1 - 17, characterized in that the active substance-containing portion consists of solid, liquid or semi-solid formulation.

19. A process for producing an administration form according to one of claims 1 - 17, characterized in that the coat free of active substance is generated by film coating, press coating, tablet coating, encapsulating or micro-encapsulating.

20. Use of an administration form according to one of claims 1 - 17 in the treatment of calcium metabolism diseases, particularly osteoporosis or hypercalcaemia.